Inhibition of HGF/MET as therapy for malignancy

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 5, 2009, Pages 569-581

  Naran, Sanjay ^a   Zhang, Xinglu ^a   Hughes, Steven J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b 497 Scaife Hall ^*  (United States)

Author keywords

Biological therapy; Hepatocyte growth factor; Scatter factor; Tyrosine kinase

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AMG 102; ANTINEOPLASTIC AGENT; ARQ 197; C MET KINASE INHIBITOR; CGEN 241; DOCETAXEL; ENZYME INHIBITOR; GELDANAMYCIN; GSK 136089; HEPATOCYTE GROWTH FACTOR ANTIBODY; HEPATOCYTE GROWTH FACTOR INHIBITOR; JNJ 38877605; K 252A; MP 470; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NEUTRALIZING ANTIBODY; RIBOZYME; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; GENE MUTATION; GLIOBLASTOMA; HUMAN; INFORMATION RETRIEVAL; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; PROGNOSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HEPATOCYTE GROWTH FACTOR; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; RNA, CATALYTIC; SIGNAL TRANSDUCTION;

EID: 67649595545     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220902853917     Document Type: Review

References (108)

1. Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med 2007;7(1):77-84 (Pubitemid 46322280)
2. Laird AD, Cherrington JM. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs 2003;12(1):51-64 (Pubitemid 36104643)
3. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7(6):504-516 · Complete review of various direct and indirect MET inhibitors, with attention to the theories of 'oncogene addiction' and 'ocogene expedience'. (Pubitemid 351767118)
4. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316(5827):1039-1043 ·· MET amplification and its role as the method of escape from EGFR inhibition. (Pubitemid 46799492)
5. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251(4995):802-804 (Pubitemid 21926175)
6. Di Renzo MF, Narsimhan RP, Olivero M. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991;6:1997-2003 (Pubitemid 21924039)
7. Tsarfaty I, Rong S, Resau JH, et al. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science 1994;263(5143):98-101 ·· A discussion of the role of MET in tumor progression. The authors would like to acknowledge Dr. Vande Woude's contribution to the study of MET, and their appreciation for his teams past and continued efforts. (Pubitemid 24076265)
8. Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376(6543):768-771
9. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373(6516):699-702
10. Chmielowiec J, Borowiak M, Morkel M, et al. c-Met is essential for wound healing in the skin. J Cell Biol 2007;177(1):151-162 (Pubitemid 46588409)
11. Neuss S, Becher E, Wöltje M, et al. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 2004;22(3):405-414 (Pubitemid 38736624)
12. Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 1999;29(3):209-248 (Pubitemid 29158969)
13. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4(12):915-925 (Pubitemid 37493640)
14. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005;15(1):49-51 (Pubitemid 41653965)
15. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22(4):309-325 (Pubitemid 36791889)
16. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77(2):261-271 (Pubitemid 24138623)
17. Nakanishi K, Fujimoto J, Ueki T, et al. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase. Clin Exp Metastasis 1999;17(6):507-514 (Pubitemid 30182745)
18. Maroun CR, Holgado-Madruga M, Royal I, et al. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 1999;19(3):1784-1799 (Pubitemid 29098237)
19. Weidner KM, Di Cesare S, Sachs M, et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996;384(6605):173-176 (Pubitemid 26386473)
20. Gu H, Neel BG. The "Gab" in signal transduction. Trends Cell Biol 2003;13(3):122-130
21. Xiao GH, Jeffers M, Bellacosa A, et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001;98(1):247-252 (Pubitemid 32095895)
22. Boccaccio C, Andò M, Tamagnone L, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998;391(6664):285-288 (Pubitemid 28099015)
23. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene, 2000;19(49):5582-5589
24. Maina F, Panté G, Helmbacher F, et al. Coupling Met to specific pathways results in distinct developmental outcomes. Mol Cell 2001;7(6):1293-1306 (Pubitemid 32607362)
25. Ridley AJ, Comoglio PM, Hall A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol 1995;15(2):1110-1122
26. Gual P, Giordano S, Williams TA, et al. Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 2000;19(12):1509-1518 (Pubitemid 30175672)
27. Apte U, Zeng G, Muller P, et al. Activation of Wnt/β-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice. Hepatology 2006;44(4):992-1002 (Pubitemid 46499261)
28. Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res 2002;62(7):2064-2071 (Pubitemid 34408453)
29. Wang R, Ferrell LD, Faouzi S, et al. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001;153(5):1023-1034 · Early in vivo demonstration of hepatocellular carcinoma secondary to MET overexpression. (Pubitemid 34289241)
30. Hepatocyte growth factor/scatter factor, Met and cancer references. Grand Rapids, MI: Van Andel Institute. Available from: www.vai.org/met/. [Last accessed 21 March 2009] ·· The Van Andel Instittute's website serves as a complete database for MET and its role in cancer.
31. Park M, Dean M, Cooper CS, et al. Mechanism of met oncogene activation. Cell 1986;45(6):895-904 (Pubitemid 16083694)
32. Marshall DD, Kornberg LJ. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 1998;108(9):1413-1417 (Pubitemid 28411378)
33. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996;74(12):1862-1868 (Pubitemid 27007128)
34. Beviglia L, Matsumoto K, Lin CS, et al. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 1997;74(3):301-309 (Pubitemid 27321800)
35. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004;10(1 Pt 1):202-211 (Pubitemid 38114181)
36. Jin L, Fuchs A, Schnitt SJ, et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 1997;79(4):749-760 (Pubitemid 27076341)
37. Guirouilh J, Le Bail B, Boussarie L, et al. Expression of hepatocyte growth factor in human hepatocellular carcinoma. J Hepatol 2001;34(1):78-83 (Pubitemid 32102555)
38. Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 2005;7(1):75-84 (Pubitemid 40209473)
39. Jucker M, Günther A, Gradl G, et al. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk Res 1994;18(1):7-16 (Pubitemid 2024258)
40. Wu CW, Li AF, Chi CW, et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 1998;5(4):817-822 (Pubitemid 28270673)
41. Otte JM, Schmitz F, Kiehne K, et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 2000;61(4):237-246 (Pubitemid 30418224)
42. Cheng HL, Liu HS, Lin YJ, et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 2005;92(10):1906-1914 (Pubitemid 40826140)
43. Cheng HL, Trink B, Tzai TS, et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 2002;20(6):1544-1550 (Pubitemid 34260534)
44. Li B, Kanamaru H, Noriki S, et al. Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Int J Urol 1998;5(5):436-440 (Pubitemid 28488198)
45. Zhu X, Humphrey PA. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 2000;56(6):1071-1074
46. Imaizumi Y, Murota H, Kanda S, et al. Expression of the c-Met proto-oncogene and its possible involvement in liver invasion in adult T-cell leukemia. Clin Cancer Res 2003;9(1):181-187 (Pubitemid 36109731)
47. Hino M, Inaba M, Goto H, et al. Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells. Br J Cancer 1996;73(1):119-123 (Pubitemid 26026272)
48. Seidel C, Børset M, Hjorth-Hansen H, et al. Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Med Oncol 1998;15(3):145-153 (Pubitemid 28496882)
49. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225(1):1-26 (Pubitemid 40732764)
50. Follenzi A, Bakovic S, Gual P, et al. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000;19(27):3041-3049 (Pubitemid 30438460)
51. Jo M, Stolz DB, Esplen JE, et al. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000;275(12):8806-8811 (Pubitemid 30180235)
52. Ma PC, Jagadeesh S, Jagadeeswaran R, et al. c-MET expression/activation, functions, and mutations in non-small cell lung cancer. Proc Am Assoc Cancer Res 2004;44:1875
53. Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19(12):1547-1555 · Correlation of MET and metastasis. (Pubitemid 30175676)
54. Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996;87(10):1063-1069 (Pubitemid 26392044)
55. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008;18(1):87-96 (Pubitemid 351694452)
56. Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer 2008;44(5):641-651
57. Toschi L, Janne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 2008;14(19):5941-5946
58. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20(1):325-334 (Pubitemid 34032628)
59. Bardelli A, Longati P, Williams TA, et al. A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J Biol Chem 1999;274(41):29274-29281 (Pubitemid 29477094)
60. Morotti A, Mila S, Accornero P, et al. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002;21(32):4885-4893 (Pubitemid 34888333)
61. Jagadeeswaran R, Jagadeeswaran S, Fackenthal J, et al. c-Met/HGF pathway in breast cancer cells and inhibition with specific small molecule inhibitor, SU11274. AACR Meeting Abstracts. 2005;2005(1):1229-a
62. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65(4):1479-1488 (Pubitemid 40270177)
63. Blazek ER, Bonomi PD, Plate J. Simultaneous inhibition of EGFR and c-Met pathways in a panel of NSCLC cell lines [abstract 22223]. J Clin Oncol 2008;2008(26 Suppl)
64. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63(21):7345-7355 (Pubitemid 37413476)
65. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006;103(7):2316-2321 (Pubitemid 43271667)
66. Jeay S, Munshi N, Hill J, et al. ARQ197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells. AACR Meeting Abstracts 2007. [Abstract 2369
67. Munshi N, Jeay S, Hill J, et al. ARQ197, a highly selective inhibitor of c-Met, inhibits invasive and metastatic growth of cancer cells. AACR Meeting Abstracts 2007. [Abstract 2367]
68. Li Y, Chen D, Zhou W, et al. Broad spectrum anti-cancer activity of ARQ197, a highly selective oral c-Met inhibitor, in multiple xenograft models. AACR Meeting Abstracts 2007. [Abstract 2216]
69. ArQule Inc. A Phase 2 study of ARQ 197 in patients with microphthalmia transcription factor associated tumors. Available from: http://clinicaltrials. gov/ct2/ show/NCT00557609 [Last accessed 21 March 2009]
70. ArQule Inc. A Phase 1 dose escalation study of ARQ 197 Given twice daily continuously in adult patients with advanced solid tumors. Available from: http://clinicaltrials.gov/ct2/show/ NCT00612209 [Last accessed 21 March 2009]
71. GlaxoSmithKline. A Phase 2 study of the MET RTK inhibitor GSK1363089 (Formerly XL880) in subjects with recurrent or metastatic squamous cell cancer of the head and neck. Available from: http://clinicaltrials.gov/ ct2/show/NCT00725764 [Last accessed 21 March 2009]
72. GlaxoSmithKline. A dose escalation study of the safety and pharmacokinetics of GSK1363089 (Formerly XL880) administered orally to subjects with solid tumors. Available from: http://clinicaltrials. gov/ct2/show/ NCT00742131 [Last accessed 21 March 2009]
73. Ross R. Srinivasan R, Vaishampayan U, et al. A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients with papillary renal carcinoma. AACR Meeting Abstracts. 2007;2007:B249
74. Srinivasan R, Choueiri TK, Vaishampayan U, et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) [abstract 5103]. J Clin Oncol 2008;26(20 Suppl)
75. Froning KJ. Felce J, Jessen K, et al. SGX-70329: a potent and highly selective small molecule inhibitor of the MET receptor tyrosine kinase. AACR Meeting Abstracts 2007 [Abstract 2366]
76. SGX Pharmaceuticals Inc. Discontinued Development of SGX523. Available from: http://www.biospace.com/news-story. aspx?NewsEntityId=96099 [Last accessed 21 March 2009]
77. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6(12 Pt 1):3314-3322
78. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67(9):4408-4417 (Pubitemid 46815090)
79. Pfizer. Phase 1 Safety, A study of oral PF-02341066, a c-Met/hepatocyte growth factor tyrosine kinase inhibitor, in patients with advanced cancer. Available from: http://clinicaltrials.gov/ ct2/show/NCT00585195 [Last accessed 21 March 2009]
80. SuperGen. MP470 and chemotherapy in treating patients with cancer. Available from: http://clinicaltrials.gov/ct2/ show/NCT00602875 [Last accessed 21 March 2009]
81. Parr C, Hiscox S, Nakamura T, et al. Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Int J Cancer 2000;85(4):563-570 (Pubitemid 30075137)
82. Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003;94(4):321-327 (Pubitemid 36626362)
83. Matsumoto K, Nakamura T. NK4 gene therapy targeting HGF-Met and angiogenesis. Front Biosci 2008;13:1943-1951 (Pubitemid 351599746)
84. Chan AM, Rubin JS, Bottaro DP, et al. Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 1991;254(5036):1382- 1385 (Pubitemid 21917475)
85. Otsuka T, Jakubczak J, Vieira W, et al. Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol Cell Biol 2000;20(6):2055-2065 (Pubitemid 30123821)
86. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007;13(22 Pt 1):6735-6742 (Pubitemid 350206811)
87. Amgen. A Phase 1b/2 Trial of AMG 479 or AMG 102 in combination with platinumbased chemotherapy as first-line treatment for extensive stage small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/ show/NCT00791154 [Last accessed 21 March 2009]
88. Amgen. A Phase II Study to Treat Advanced Malignant Glioma. Available from: http://clinicaltrials.gov/ct2/show/ NCT00427440 [Last accessed 21 March 2009]
89. Amgen. A Phase II study to treat subjects with advanced renal cell carcinoma. Available from: http://clinicaltrials.gov/ct2/ show/NCT00422019 [Last accessed 21 March 2009]
90. Mazzone M, Basilico C, Cavassa S, et al. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 2004;114(10):1418-1432 (Pubitemid 40385573)
91. Michieli P, Basilico C, Pennacchietti S, et al. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 1999;18(37):5221-5231 (Pubitemid 29460658)
92. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6(1):61-73 (Pubitemid 38903162)
93. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17(4):361-373 · Detailed review of the role of geldanamycin in MET inhibition. (Pubitemid 30135903)
94. Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-Met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000;60(2):342-349 (Pubitemid 30070761)
95. Abounader R, Ranganathan S, Lal B, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 1999;91(18):1548-1556 (Pubitemid 29457959)
96. Betsunoh H, Mukai S, Akiyama Y, et al. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci 2007;98(4):491-498 (Pubitemid 46562738)
97. Ayhan A, Ertunc D, Tok EC, Ayhan A. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer 2005;15(4):618-623 (Pubitemid 41022899)
98. Ide T, Kitajima Y, Miyoshi A, et al. The hypoxic environment in tumorstromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol 2007;14(9):2600-2607 (Pubitemid 47389573)
99. Rong S, Jeffers M, Resau JH, et al. Met expression and sarcoma tumorigenicity. Cancer Res 1993;53(22):5355-5360 (Pubitemid 23342148)
100. Fukuda T, Ichimura E, Shinozaki T, et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 1998;48(10):757-762 (Pubitemid 28455692)
101. Rees H, Williamson D, Papanastasiou A, et al. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors 2006;24(3):197-208 (Pubitemid 44669350)
102. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997;57(23):5391-5398 (Pubitemid 27516379)
103. Li Y, Lal B, Kwon S, et al. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 2005;65(20):9355-9362 (Pubitemid 41508003)
104. Gao L, Feng Y, Bowers R, et al. Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res 2006;66(16):7880-7888 (Pubitemid 44299150)
105. Hecht M, Papoutsi M, Tran HD, et al. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res 2004;64(17):6109-6118 (Pubitemid 39129411)
106. Kim KJ, Wang L, Su YC, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006;12(4):1292-1298 (Pubitemid 43342521)
107. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. A safety and dose-finding study of JNJ-38877605 in patients with advanced or refractory solid tumors. Available from: http://clinicaltrials.gov/ct2/show/ NCT00651365 [Last accessed 21 March 2009]
108. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12(20 Pt 1):6144-6152 (Pubitemid 44703780)